Your session is about to expire
What is Integrilin
EptifibatideThe Generic name of this drug
Treatment SummaryEptifibatide is a synthetic peptide derived from the venom of the Southeastern pygmy rattlesnake. It is a cyclic heptapeptide that works by binding to a platelet receptor and blocking platelet aggregation. This drug is part of a class of drugs known as arginin-glycin-aspartat-mimetics.
Integrilinis the brand name
Integrilin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Integrilin
Eptifibatide
1998
42
Approved as Treatment by the FDA
Eptifibatide, otherwise known as Integrilin, is approved by the FDA for 2 uses like Angioplasty and Acute Chest Syndrome .Angioplasty
Helps manage Percutaneous Coronary Intervention (PCI)
Acute Chest Syndrome
Helps manage Acute Coronary Syndrome (ACS)
Effectiveness
How Integrilin Affects PatientsEptifibatide is a drug that prevents blood from clotting by blocking a receptor on platelets. It works quickly and can be reversed.
How Integrilin works in the bodyEptifibatide stops blood platelets from sticking together. It does this by blocking a receptor on the platelets that binds to other molecules like fibrinogen. When the receptor is blocked, the platelets cannot stick to each other, preventing clotting.
When to interrupt dosage
The suggested measure of Integrilin is contingent upon the confirmed condition, including Acute Chest Syndrome, Angioplasty and Coronary Stents. The amount of dosage varies, in regard to the mode of delivery (e.g. Injection, solution or Intravenous) depicted in the table below.Condition
Dosage
Administration
Acute Chest Syndrome
0.75 mg/mL, , 2.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Angioplasty
0.75 mg/mL, , 2.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Coronary Stent Implantation
0.75 mg/mL, , 2.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Warnings
Integrilin has eight contraindications and should not be administered for the conditions identified in the following table.Integrilin ContraindicationsCondition
Risk Level
Notes
Operative Surgical Procedures
Do Not Combine
Hemorrhagic Stroke
Do Not Combine
Pulse Frequency
Do Not Combine
Hypertensive disease
Do Not Combine
Abnormal Bleeding
Do Not Combine
history of stroke
Do Not Combine
Hemodialysis
Do Not Combine
history of bleeding diathesis
Do Not Combine
Common Integrilin Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Eptifibatide is combined with Abrocitinib.
Aldesleukin
Minor
The risk or severity of bleeding can be increased when Eptifibatide is combined with Aldesleukin.
Alemtuzumab
Minor
The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.
Altretamine
Minor
The risk or severity of bleeding can be increased when Eptifibatide is combined with Altretamine.
Amsacrine
Minor
The risk or severity of bleeding can be increased when Eptifibatide is combined with Amsacrine.
Integrilin Toxicity & Overdose RiskIn tests on rats, rabbits, and monkeys, eptifibatide was found to not be lethal when given as a continuous intravenous infusion at a dose of 45mg/kg for 90 minutes, which is about 2 to 5 times the maximum recommended daily dose for humans.
Integrilin Novel Uses: Which Conditions Have a Clinical Trial Featuring Integrilin?
Currently, 10 active trials are evaluating the potential of Integrilin as a treatment for Angioplasty, Coronary Stents and Acute Chest Syndrome.Condition
Clinical Trials
Trial Phases
Coronary Stent Implantation
0 Actively Recruiting
Acute Chest Syndrome
1 Actively Recruiting
Not Applicable
Angioplasty
8 Actively Recruiting
Phase 3, Phase 4, Not Applicable, Phase 1, Phase 2
Integrilin Reviews: What are patients saying about Integrilin?
1Patient Review
5/13/2009 I'm a 66 year old male and I had a bad allergic reaction to this drug during a prior procedure. Despite this, the MD still choose to use it which resulted in me bleeding out in my lungs. I was intubated for 7 days and spent 16 days total in the hospital. Please be sure that your doctor and hospital staff are aware of any allergies you have before undergoing any procedures.
1Patient Review
11/6/2008 Unfortunately, I had a really bad reaction to this treatment. My platelets dropped from 318,000 down to 1,000 and I started bleeding from my mouth and developed blood spots on my hands and thighs. I needed a transfusion of six units of platelets to bring it back up to 34,000.
1Patient Review
10/20/2011 My brother was given this medication and is now hospitalized, intubated, and waiting on a pulmonologist and neurologist.
Patient Q&A Section about integrilin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is INTEGRILIN still used?
"Integrilin is a medication used to prevent blood clots or heart attacks in people with severe chest pain or other conditions, as well as those who are undergoing a procedure called angioplasty. It may also be used for other purposes not listed in this guide."
Answered by AI
What is the mechanism of action of INTEGRILIN?
"Eptifibatide prevents blood clots by inhibiting the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa."
Answered by AI
What kind of drug is INTEGRILIN?
"Integrilin is a prescription medication used to treat Acute Coronary Syndrome and Percutaneous Coronary Intervention. It may be used alone or with other medications. Integrilin belongs to a class of drugs called antiplatelet agents and cardiovascular glycoprotein IIb/IIIa inhibitors."
Answered by AI
What is INTEGRILIN used for?
"Integrilin helps prevent blood clots by stopping platelets from sticking together. It is used in people with unstable angina to help prevent heart attacks and death."
Answered by AI